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Abstract
Niemann-Pick C disease (NP-C) is a neurovisceral atypical lysosomal lipid storage disorder with an estimated minimal 
incidence of 1/120 000 live births. The broad clinical spectrum ranges from a neonatal rapidly fatal disorder to an adult-
onset chronic neurodegenerative disease. The neurological involvement defines the disease severity in most patients 
but is typically preceded by systemic signs (cholestatic jaundice in the neonatal period or isolated spleno- or 
hepatosplenomegaly in infancy or childhood). The first neurological symptoms vary with age of onset: delay in 
developmental motor milestones (early infantile period), gait problems, falls, clumsiness, cataplexy, school problems 
(late infantile and juvenile period), and ataxia not unfrequently following initial psychiatric disturbances (adult form). 
The most characteristic sign is vertical supranuclear gaze palsy. The neurological disorder consists mainly of cerebellar 
ataxia, dysarthria, dysphagia, and progressive dementia. Cataplexy, seizures and dystonia are other common features. 
NP-C is transmitted in an autosomal recessive manner and is caused by mutations of either the NPC1 (95% of families) 
or the NPC2 genes. The exact functions of the NPC1 and NPC2 proteins are still unclear. NP-C is currently described as a 
cellular cholesterol trafficking defect but in the brain, the prominently stored lipids are gangliosides. Clinical 
examination should include comprehensive neurological and ophthalmological evaluations. The primary laboratory 
diagnosis requires living skin fibroblasts to demonstrate accumulation of unesterified cholesterol in perinuclear vesicles 
(lysosomes) after staining with filipin. Pronounced abnormalities are observed in about 80% of the cases, mild to 
moderate alterations in the remainder ("variant" biochemical phenotype). Genotyping of patients is useful to confirm 
the diagnosis in the latter patients and essential for future prenatal diagnosis. The differential diagnosis may include 
other lipidoses; idiopathic neonatal hepatitis and other causes of cholestatic icterus should be considered in neonates, 
and conditions with cerebellar ataxia, dystonia, cataplexy and supranuclear gaze palsy in older children and adults. 
Symptomatic management of patients is crucial. A first product, miglustat, has been granted marketing authorization 
in Europe and several other countries for specific treatment of the neurological manifestations. The prognosis largely 
correlates with the age at onset of the neurological manifestations.
Disease definition
Historical delineation
Coined in the late 1920's from the pioneering work of
Albert Niemann and Ludwig Pick, the eponym "Nie-
mann-Pick disease" has since been used to designate a
heterogeneous group of autosomal recessive lysosomal
lipid storage disorders, with common features of hepatos-
plenomegaly and sphingomyelin storage in reticuloen-
dothelial and parenchymal tissues, with or without
neurological involvement. In 1958, Crocker and Farber
showed that there was a wide variability in age of onset
and clinical expression, as well as in the level of sphingo-
myelin storage in tissues [1]. This led Crocker to propose
a classification into four subgroups, A to D [2]. Type A
was characterized by severe, early CNS deterioration and
massive visceral and cerebral sphingomyelin storage.
T ype  B  s howed a  c hr oni c c ou rse  wit h m ar k ed visc e ra l
involvement but a sparing of the nervous system. Types C
and D were characterized by a sub acute nervous system
involvement with a moderate and slower course and a
milder visceral storage. Type D patients were individual-
ized essentially on their homogenous Nova Scotia Aca-
dian origin. In 1966, Brady and associates [3]
demonstrated a severe deficiency in sphingomyelinase
activity in tissues from patients with type A, a finding
soon extended to type B, but not to types C and D, indi-
cating that the two latter types constituted separate enti-
ties. From that time on, with a turn following seminal
observations in a Balb/c murine model of the disorder [4],
the concept of Niemann-Pick type C disease evolved
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from that of a sphingomyelin storage disorder to that of a
cholesterol storage disorder [5]. This and later work led
to the reclassification of type C as a cellular lipid traffick-
ing disorder, involving more specially, but not only, endo-
cytosed cholesterol.
Definition of Niemann-Pick disease type C
Today, by definition, "Niemann-Pick C disease" encom-
passes disorders characterized by unique abnormalities of
intracellular transport of endocytosed cholesterol with
sequestration of unesterified cholesterol in lysosomes
and late endosomes [5-12]. Major advances have been the
description of two genetic complementation groups
[13,14] and the subsequent isolation of the two underly-
ing genes [15,16]. NPC1 is involved in 95% of the families
[14], including those with type D [17]. NPC2 is involved
in rare families (about 30 are known to date). Although
the precise functions of the NPC1 and NPC2 proteins are
still elusive, current knowledge supports the idea that
these proteins function in a coordinate fashion and that
they are involved in the cellular postlysosomal/late endo-
somal transport of cholesterol and other molecules [10-
12,18,19].
Niemann-Pick diseases thus oppose two clearly distinct
groups: acid sphingomyelinase deficiencies (due to
SMPD1 mutations, including types A, B and intermediate
forms,) and Niemann-Pick type C, with alterations in
trafficking of endocytosed cholesterol (due to NPC1 or
NPC2 mutations). Type D as a distinct entity is no longer
justified. From a practical standpoint, no patient should
today be longer qualified of suffering from "Niemann-
Pick disease" without specification of the subgroup, either
acid sphingomyelinase deficiency or type C.
Disease name and synonyms
"Niemann-Pick disease type C" (or "Niemann-Pick C dis-
ease"), often abbreviated as NP-C (or NPC), is currently
the generic name widely used to designate the condition,
irrespective of which gene, NPC1 or NPC2, is mutated.
This term now encompasses the historical Niemann-Pick
disease type D referring to the "Nova Scotia" isolate, later
shown to be a genetic NPC1 variant [17]. Instead, a subdi-
vision is sometimes made between Niemann-Pick C1
(NP-C1) or C2 (NP-C2), according to the gene involved.
Patients with a retrospective diagnosis of Niemann-Pick
C disease have also been described in the 1960s and
1970s as juvenile Niemann-Pick disease, juvenile dystonic
lipidosis, atypical cerebral lipidosis, neurovisceral storage
disease with vertical supranuclear ophthalmoplegia, mal-
adie de Neville, DAF (down-gaze paresis, ataxia, foam
cell) syndrome, adult dystonic lipidosis, adult neurovis-
ceral lipidosis, giant cell hepatitis, and lactosylceramido-
sis [10,20].
Epidemiology
NP-C (either NP-C1 or NP-C2) shows autosomal reces-
sive inheritance and is panethnic. The true prevalence of
NP-C is difficult to assess, because of insufficient clinical
a wareness combined with the relative difficulty of bio-
chemical testing. Estimates of birth prevalence ranging
between 0.66 and 0.83 per 100,000 were proposed for
France, the UK and Germany based on diagnoses made in
the laboratory of the author over the period 1988-2002
[10,11]. However, very different figures of 0.47, 0.35 and
2.20 per 100,000, respectively, were reported in studies
from Australia (20 cases between 1980-1996), The Neth-
erlands (25 cases between 1970-1996) and Northern Por-
tugal (9 cases 1985-2003) [21-23]. The low incidence
found for Australia and the Netherlands might be
explained by a non- exhaustivity of the diagnoses in the
years of birth of many patients. The wide clinical spec-
trum of NP-C was not recognized until the early 1990s,
especially regarding rapidly fatal infantile cases, and no
specific laboratory testing was available until the mid
1980s. For this review, an updated incidence of 0.82/
100,000 was calculated for France, considering the total
number of cases (n = 63) diagnosed for French hospitals
during the 2000-2009 period vs. the number of births
during the same period, a possibly more appropriate way
of calculation. This value should be considered as a mini-
mal estimate, since atypical phenotypes may not be sus-
p e c t e d  c l i n i c a l l y  o r  m a y  b e  m i s s e d  b y  t h e  d i a g n o s t i c
laboratory. Including prenatal cases from terminated
pregnancies during the same period (n = 11) increased
the incidence to 0.96 per 100,000.
Most families (about 95%) belong to the NP-C1 group.
Two NP-C1 isolates have been described. The first one, in
French Acadians originating from Normandy and origi-
nally established in Nova Scotia, was initially described as
Niemann-Pick disease type D; it is characterized by the
NPC1 p.G992W mutation [1, 17, and 24]. Another isolate
was described in Hispanics from southern Colorado and
New Mexico with their roots in the Upper Rio Grande
valley of the USA, carrying the NPC1 p. I1061T mutation
[25,26].
Clinical Description
The clinical presentation of NP-C is extremely heteroge-
neous, with an age of onset ranging from the perinatal
period until well into adult age (as late as the seventh
decade of life). Similarly, the lifespan of the patients varies
between a few days until over 60 years of age, although a
majority of cases die between 10 and 25 years of age
[10,11,27-30]. The clinical spectrum discussed below has
been analyzed from several large surveys [28-35].
NP-C is classically a neurovisceral condition. Impor-
tantly, visceral involvement (of liver, spleen, and some-
times lung) and neurologic or psychiatric manifestationsVanier Orphanet Journal of Rare Diseases 2010, 5:16
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arise at different times, and they also follow completely
independent courses. Apart from a small subset of
patients who die at birth, or in the first 6 months of life
from hepatic or respiratory failure, and exceptional adult
cases, all patients ultimately will develop a progressive
and fatal neurological disease. Systemic disease, when
present, always precedes onset of neurological symp-
toms, but the systemic component may be absent or min-
imal in approximately 15% of all patients, and close to half
of the adult-onset patients, at least at the time of diagno-
sis. In typical patients, the neurologic disorder consists
mainly of cerebellar ataxia, dysarthria, dysphagia, and
progressive dementia, and the majority of cases show a
characteristic vertical supranuclear gaze palsy (VSGP)
[36]. Cataplexy, seizures, and dystonia are other quite
common features, and psychiatric disturbances are fre-
quent in late-onset patients. The proper recognition of
VSGP is essential but this sign is often overlooked at an
early stage, because slow pursuit is often maintained
although saccade velocity is already impaired. Cataplexy
(with or without narcolepsy), usually laughter-induced, is
another more specific symptom [37,38]. Except for the
perinatal period, the systemic disease is usually not very
severe and is well tolerated. The splenomegaly has been
described to fluctuate and to decrease with time. Severe
lung involvement has been reported in a few patients but
is not frequent.
A description of the various clinical forms by age cate-
gories has been used in recent reviews [10,11,27] and will
also be followed in this summary. Detailed complemen-
tary information can be obtained in [27]. For each age
category except for the perinatal presentations, one
should however distinguish patients entering the disease
by systemic involvement [39] from those who are starting
then their neurological disease (although they may have
presented earlier with visceral symptoms). Of essential
importance is to note that the age of onset of the systemic
symptoms is not related with that of the neurological dis-
ease (the latter can occur many years or even decades
later), while there is a correlation between the age of
onset of the neurological symptoms and the general fur-
ther course of the disease and lifespan (Fig. 1). Categoriz-
ing patients by forms based on the age range of onset of
the neurological symptoms`[11,32,40], irrespective of the
age of the first symptom, is very useful for genetic coun-
seling, natural history studies and also in clinical practice.
With an exception for the severe early infantile neurolog-
ical form which is quite significantly distinct, recent large
studies have however demonstrated an overlap between
the neurological forms, and thus a continuum [27]. A
schematic representation is proposed in Fig. 2.
Perinatal presentation
Niemann-Pick C disease is now recognized as a relatively
common cause of liver disease in early life. Fetal hydrops
or fetal ascites can be observed [28]. Above all, a pro-
longed neonatal cholestatic icterus, appearing in the first
days or weeks of life and usually associated with progres-
sive hepatosplenomegaly is present in close to half of
patients, although with very variable intensity [29,41,42].
In most cases, the icterus resolves spontaneously by 2 to 4
months of age, and only hepatosplenomegaly remains for
a highly variable period, preceding onset of neurologic
symptoms (see below). In about 10% of these patients,
however, the icterus quickly worsens and leads to liver
failure. Children with this dramatic "acute" neonatal
cholestatic rapidly fatal form usually die before the age of
6 months [29]. Some other infants, especially (but not
exclusively) those having mutations in the NPC2 gene,
present with a severe respiratory insufficiency (together
with hepatosplenomegaly or more severe liver disease)
that may also be fatal. In two patients, lung lavage, radiol-
ogy and histology showed signs of pulmonary alveolar
lipoproteinosis [43,44]. Patients with NP-C do not show
neurological manifestations during the neonatal period
(important for differential diagnosis). But there are many
examples of patients dying from a severe perinatal form
having siblings with a neurologic infantile or juvenile
onset form [11,29].
Early infantile period (2 months-2 years)
Systemic stage
An isolated hepatosplenomegaly can be discovered at this
age period, which may well stay isolated for many years,
in spite of the early onset. Once the diagnosis of NP-C is
made, a regular neuropediatric follow up should be initi-
ated.
Figure 1 Age of onset of neurological disease vs lifespan. Study on 
97 cases for whom appropriate clinical information was available from 
the cohort of 181 patients originating from French hospitals. Each hor-
izontal bar depicts one patient. The green color indicates the period 
during which the patient did not present neurological symptoms, irre-
spective of the presence or absence of preexisting systemic disease. 
Patients who died in their first days or months of life from systemic dis-
ease (n = 19) are not shown on this graph.
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Severe early infantile neurologic onset form
In these infants, hepatosplenomegaly has almost invari-
ably been present since birth or the first months of life.
Delay of developmental motor milestones from the age of
8-9 months and central hypotonia constitute the first
neurologic symptoms, which become evident between
the age of 1 and 2 years. Subsequent clinical course
includes a loss of acquired motor skills, proportionally
less marked mental regression, followed by pronounced
spasticity with pyramidal tract involvement. Many of
these children never learn to walk. Intention tremor is
frequently present; supranuclear gaze palsy is usually not
recognized. Seizures are uncommon. Brain imaging (MRI
and MRS) shows signs of leukodystrophy and cerebral
atrophy. Survival rarely exceeds 5 years. This form seems
to be more frequent in Southern Europe (where it consti-
tutes >20% of the cases) and the Middle East [11,29,32].
Late infantile period (2 to 6 years)
Systemic stage
Many patients start their disease by discovery of an iso-
lated hepatosplenomegaly or splenomegaly during this
period. Regular neuropediatric follow-up should be initi-
ated, as above.
Late infantile neurologic onset form
Hepatosplenomegaly has almost invariably been present
for a varying length of time. Language delay is frequent.
The child often presents with gait problems, frequent
falls and clumsiness between 3 and 5 years of age, due to
ataxia. VSGP is usually present but may not be recog-
nized at an early stage. Hearing loss has also been
described. Cataplexy develops relatively frequently and
may occasionally be the presenting symptom. The motor
problems worsen, and impairment in mental develop-
ment becomes more obvious. A significant proportion of
patients develop seizures which may be partial, general-
ized, or both. They generally respond to standard treat-
ment but refractory cases may occur, with some patients
dying from status epilepticus or complications of sei-
zures. Severe epilepsy has a bad prognosis and signifi-
cantly shortens the lifespan of the patients. As ataxia
progresses, dysphagia, dysarthria, and dementia develop.
At later stages, the patients develop pyramidal signs and
spasticity, and pronounced swallowing problems. Most
Figure 2 Niemann-Pick disease type C as a neurovisceral disease. Schematic representation of the main forms of the disease, with particular em-
phasis on type and age of onset of first neurological symptoms
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require gastrostomy. Death most often occurs between 7
to 12 years in this form.
Juvenile period (6-15 years) (classical form)
Systemic stage
Discovery of an isolated splenomegaly (or, rarely, of a
hepatosplenomegaly) at this period may again be the
inaugural sign of the disease, and these patients should
later be appropriately monitored.
Juvenile neurologic onset form
This constitutes in most countries the most common
form of the disease. A moderate splenomegaly (or hepa-
tosplenomegaly) is frequent, and may have been detected
at any earlier time, including the neonatal period. How-
ever, cases in whom a splenomegaly had been noted in
early childhood but is hardly detectable at the time first
neurological symptoms arise are not rare; and absence of
a detectable organomegaly has been reported to occur in
at least 10% of cases. School problems with difficulties in
writing and impaired attention are very common and
may lead to misdiagnosis. The disease may also mimic
dyspraxia. VSGP is almost invariably present and often
the initial sign. The child becomes clumsier and shows
more learning disabilities. Cataplexy, with or without nar-
colepsy, typically laughter-induced, is another common
symptom. Ataxia soon becomes obvious, with frequent
falls and difficulties to run, and progresses at a variable
rate. Dysarthria develops, as well as dysphagia. Action
dystonia is also frequent, Motor impairment is major and
intellectual decline may be variable. About half of the
patients with the classic form develop seizures of variable
type and severity (see above). At a later stage, dysarthria
worsens and patients often stop talking. At a late stage,
patients develop pyramidal signs and spasticity, and pro-
nounced swallowing problems, requiring gastrostomy.
The lifespan is quite variable, some patients being still
alive by age 30 or later [27].
Adolescent and adults (>15 years)
Systemic adult form of NP-C
The finding of three patients aged 53-63 years with iso-
lated splenomegaly and a biochemical and molecular
diagnosis of NP-C [45-48] suggests the existence of a rare
non-neuronopathic form of the disease (possibly corre-
sponding to the ill-described historical "type E"). Never-
theless, apart from these exceptional cases and from
infants with early death, as stated above, all NP-C
patients develop neurologic symptoms.
Adult neurologic onset form
More patients with a neurologic adult onset form of the
disease (often in the second or third decade, but as late as
50 years or older) have been described in recent years
[30,35,49-53] This diagnosis is probably underestimated.
Absence of clinically detectable splenomegaly has been
reported in a significant proportion of patients but
abdominal sonography may reveal a slightly enlarged
spleen. VSGP is usually present but may also be missing.
The most common symptomatology is that of an attenu-
ated juvenile form with an insidious onset, with in at least
one third of cases, a psychiatric presentation that may be
isolated for several years before the onset of motor and
cognitive signs. Psychiatric signs are most often consis-
tent with psychosis, including paranoid delusions, audi-
tory or visual hallucinations, and interpretative thoughts.
Onset may be acute or progressive, eventually with
relapses. At this stage the neurologic examination may be
normal. Other types of psychiatric disturbances are
depressive syndrome, behavioral problems with aggres-
siveness, or social isolation. Cases have also been
reported with bipolar disorders, obsessive-compulsive
disorders, or transient visual hallucinations. From compi-
lation of the literature [35] the most common features
are: cerebellar ataxia (76%), vertical supranuclear oph-
thalmoplegia (75%), dysarthria (63%), cognitive troubles
(61%), movement disorders (58%), splenomegaly (54%),
psychiatric disorders (45%) and dysphagia (37%). Move-
ment disorders (dystonia, Parkinsonism, chorea) are
more frequent than in the juvenile form. Some patients
show severe ataxia, dystonia, and dysarthria with variable
cognitive dysfunction, whereas psychiatric symptoms and
dementia dominate in others. Epilepsy is rare in adult
onset NP-C (15%). Later course is similar to that in the
juvenile form.
Etiology
Mutations in either of the two genes, NPC1 or NPC2,
may cause the disease [13-16]. Approximately 95% of
patients have mutations in the NPC1  gene, which
encodes a large membrane glycoprotein with mostly a
late endosomal localization [54]. The remainder have
mutations in the NPC2 gene, which encodes a small solu-
ble lysosomal protein that binds cholesterol with high
affinity [16,55,56]. Mutations in the NPC1 or NPC2 genes
result in a similar cellular lesion, including a unique
impairment in processing and utilization of endocytosed
cholesterol that could explain cholesterol storage and sec-
ondary alterations of sphingomyelin metabolism in extra
neural tissues. Glycolipids and free sphingosine/sphinga-
nine storage also occurs. In brain, - more specifically in
neurons - the dominant lipid accumulation is in fact that
of GM2 and GM3 gangliosides, with only limited appar-
ent abnormalities of cholesterol (see below). Early studies
in cells and tissues from NP-C1 and NP-C2 patients could
not disclose any biochemical marker that was specific to
any of the groups, suggesting that both proteins may
function in tandem or sequentially [14]. Comparison
between double mutant mice deficient in both NPC1 and
NPC2 and the single mutants demonstrated a non-Vanier Orphanet Journal of Rare Diseases 2010, 5:16
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redundant functional cooperativity of the two proteins in
a common pathway for lipid cellular transport, which
strengthened this concept [18]. The exact functions of the
NPC1 and NPC2 proteins are still unclear [10-12,56,57],
which greatly complicates understanding of the
pathophysiology. Neuronal storage with meganeurite for-
mation and extensive growth of ectopic dendrites, as well
as formation of neurofibrillary tangles, are important
neuropathological features together with neuroinflam-
mation and neuroaxonal dystrophy. As the disease pro-
gresses, neuronal death becomes prominent, affecting
more specifically certain regions, particularly Purkinje
cells of the cerebellum, but the basis of this selective neu-
ronal vulnerability is still unknown [10,58].
Lipid accumulation in tissues
Similar profiles have been observed in NP-C1 and NP-C2
patients (and animal models), but the pattern of accumu-
lating lipids is different in brain and in non-neural organs
[10,18,20,40,59-64]. In liver and spleen, a complex pat-
tern, with no predominating compound, is observed.
Accumulated lipids include unesterified cholesterol and
sphingomyelin (2- to 5-fold increase in human patients),
bis(monoacylglycerol) phosphate (also named LBPA or
BMP), glycolipids (essentially glucosylceramide and lac-
tosylceramide), and free sphingosine and sphinganine. In
human patients, the level of storage is more pronounced
in the spleen than in the liver, where changes may be sub-
tle. In brain tissue, neither cholesterol nor sphingomyelin
overtly accumulate, but significant alterations of gly-
cosphingolipids occur, especially for gangliosides GM2
and GM3 (10-20 fold increase). Free sphingosine levels
are much less elevated in brain (x3) than in liver or spleen
(x20) [62,64]. Myelin lipids are markedly affected in the
NPC1 mouse model but in patients, a significant decrease
is only seen in the early infantile neurological onset form
[18,60].
Cell biology and cholesterol transport, and the brain 
enigma
Initial studies by Peter Pentchev and associates and fur-
ther work from several laboratories (reviewed in [10,20])
demonstrated, in cultured skin fibroblasts of Niemann-
Pick C disease patients, a disruption in intracellular
transport of endocytosed cholesterol. Endocytosed low
density lipoproteins are delivered to late endosomes/lyso-
somes, where they are hydrolyzed, so that free cholesterol
is released. In normal cells, this cholesterol is transported
rapidly out of endosomes to the plasma membrane and
the endoplasmic reticulum. In Niemann-Pick C disease
cells (either NPC1 or NPC2), the cholesterol does not exit
the endocytic pathway but accumulates within lyso-
somes. This anomaly constitutes the cellular hallmark of
the disease. Due to this sequestration, the subsequent
induction of all low-density lipoprotein cholesterol-medi-
ated homeostatic responses (more specially cholesteryl
ester formation) is retarded in Niemann-Pick C disease
cells. Normal responses can be induced by membrane-
permeable oxysterol and by mevalonate, showing that the
ability of the cell to respond is maintained. Very recently,
it was further shown that the block in cholesterol delivery
to the ER can also be overcome by 2-hydroxypropyl-beta-
cyclodextrin [65], and that this compound added to fibro-
blasts reduces the lysosomal cholesterol accumulation
[66]. Studies in patients' cells showed that lysosomal stor-
age of unesterified cholesterol may show a variable inten-
sity, and a "variant" biochemical phenotype with mild
abnormalities has been described [67,68]. Later work
showed that this phenotype was underlined by specific
NPC1 mutations (see below). Unexpectedly, fibroblasts
from a large proportion of obligate heterozygotes have
been found to show mild but definite changes [67-70].
This unique impairment in processing and utilization
of endocytosed cholesterol obviously plays a key role in
the pathogenesis of Niemann-Pick C disease, and, at least
in extraneural organs, could actually explain a more gen-
eral dysfunction of intracellular metabolism of lipids [63].
Sphingomyelin accumulation appears related to lyso-
somal cholesterol storage, since sphingomyelinase activ-
it y ca n be  s t r ongl y m odula t ed in fibr o blas t  cul t u r es  of
Niemann-Pick C disease patients by incubation in pres-
ence or absence of low-density lipoprotein. Cholesterol
accumulation might also modulate glucosylceramide
hydrolysis [71], as well as the trafficking of late endo-
somal proteins such as Rab 9 and mannose-6-phosphate
receptors [72], two key players in the normal function of
the endosomal/lysosomal system. There is thus good evi-
dence that cholesterol accumulation in the late endo-
somal/lysosomal compartment can impair vesicular
trafficking pathways.
The pathogenesis of the neuronal dysfunction appears
by far more complex, since brain cholesterol is synthe-
sized locally, mostly by oligodendroglial cells and to a
lesser extent by astrocytes and neurons. Neurons might
also acquire a small amount of cholesterol by glial deliv-
ery through apo-E uptake [73]. By chemical measure-
ment, no significant increase of cholesterol
concentrations can be found in dissected cerebral grey
matter from human patients [60]. In situ labeling using
filipin histochemistry, however, reveals a sequestration of
unesterified cholesterol in cell bodies of neurons and glia
of single NPC1 or NPC2 mutant mice as well as those of
the double mutant [18,58,73-75]. These observations are
not necessarily contradictory, since studies on cultured
sympathetic neurons from NPC1 mutant mice gave indi-
cation that cholesterol did accumulate in cell bodies, but
was decreased in distal axons, leading to a distribution
imbalance [76,77]. One group has reported that endoge-Vanier Orphanet Journal of Rare Diseases 2010, 5:16
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nously synthesized cholesterol may significantly contrib-
ute to the overall cholesterol accumulation observed in
Niemann-Pick C disease in various cell types, including
glial cells [78]. Nevertheless, since abnormal filipin stain-
ing of neurons is also observed in a wide spectrum of
other lysosomal storage disorders [discussed in 63], the
exact participation of cellular cholesterol transport
abnormalities in the pathophysiology of the neurodegen-
erative NP-C disease remains elusive. Of note, fibroblasts
from patients with an adult-onset of neurological symp-
toms may show either a severe cholesterol trafficking
defect or only minimal alterations (biochemical variant)
[35,69,70]. Conversely, in two "variant" siblings who had
died from a juvenile form, the liver showed no lipid accu-
mulation (spleen did), but the brain showed typical accu-
mulation of GM2 and GM3 gangliosides [79].
The NPC1 and NPC2 proteins
The mature native NPC1 is a large (1252 amino acids)
glycoprotein with 13 transmembrane domains, that
resides primarily in late endosomes and interacts tran-
siently with lysosomes and the trans-Golgi network
[54,80]. It possesses a sterol-sensing domain (amino acid
residues 615-797) showing homologies with those of
HMG-CoA reductase, SCAP, patched and NPC1L, the
exact role of which is still unclear although it appears
necessary for protein function. Two luminal domains may
play a role in protein-protein interactions: a cysteine-rich
loop with a ring-finger motif which harbors about 1/3 of
the mutations described in patients (amino acid residues
855-1098), and a highly conserved domain with a leucine-
zipper motif, located in the N-terminal tail (amino acids
25-264) [81]. Importantly, the latter has been shown to
possess a cholesterol-binding site (reviewed in [56]).
Contrary to the NPC1 protein, the NPC2 protein is small
(132 amino acids), soluble, secreted and recaptured. It is
transported to the lysosome via the mannose-6-phos-
phate receptor and binds cholesterol with submicromolar
affinity [56]. The mutation p.S120P (observed in a patient
with a juvenile neurological onset and slowly progressive
form [82]) has been instrumental to confirm the func-
tional significance of the cholesterol-binding site of the
NPC2 protein [83]. Studies in patients and animal models
have shown that both NPC2 and NPC1 are required for
cholesterol egress from the lysosome. Binding of choles-
terol to NPC1 and dissociation both appear accelerated
by NPC2 [83]. Based on the current stage of knowledge
but fully compatible with earlier studies (reviewed in
[56]) a "handoff" model has recently been proposed for
the coordinated role of the two proteins [19]. In this
model, cholesterol released within the lysosome binds to
NPC2 with its hydroxyl group exposed; a transfer to the
N-terminal domain of NPC1 occurs reversing its orienta-
tion, so that the hydrophobic side chain could lead the
way into the membrane and/or the glycocalix. The most
recent studies [65] indicate that the role of NPC2/NPC1
p r o t e i n s  i n  c h o l e s t e r o l  t r a n s p o r t  i s  r e s t r i c t e d  t o  l y s o -
somal export. Current data suggest that retrograde cho-
lesterol movement from the plasma membrane to the ER
does not require NPC1 [65] and implication of these pro-
teins in cell processing of endogenously synthesized cho-
lesterol [84] is still a matter of discussion.
Many uncertainties thus remain regarding the precise
and complete functions of the NPC1 and NPC2 proteins.
It has also been suggested that they could be involved in
fusion/fission events between the late endosome and the
lysosome. One important (and yet unanswered) question
is whether these proteins - at least NPC1 - also directly
regulate or mediate retrograde transport of other lyso-
somal cargo. Glycolipids, which constitute the main lipid
accumulation in the brain, by opposition to the quantita-
tively minor cholesterol imbalance in neurons, are good
candidates. The storage of GM2 and GM3 gangliosides in
brain is not specific. Yet, the increase of GM2 occurs
much earlier and is more prominent in NP-C than in
other lysosomal diseases [63]. But no data supportive of a
glycolipid transport by NPC1 or NPC2 have been pub-
lished so far. It has also been postulated that sphingosine
storage could be the primary trigger of a pathogenic cas-
cade in NP-C since this lipid can disrupt calcium homeo-
stasis in NPC1 lysosomes [85,86]. The latter studies,
however, were conducted in non neural NP-C cells or in a
drug (U18666A)-induced model. In brain, currently avail-
able data show a close link between accumulation of the
different lipids, both in developmental terms and after
therapeutic attempts [63,64]. No ganglioside or sphin-
gosine accumulation can be detected in the brain of
human fetuses at 24 gestational weeks, although the liver
already shows a pronounced storage. Arguments for and
against each of the accumulated lipids as the offending
metabolite have recently been discussed [86]. Most likely,
stored lipids (and possibly other metabolites) collectively
contribute to the pathology. More work is clearly needed
to better understand the cause of brain dysfunction in
Niemann-Pick C disease. In particular, the mechanisms
by which Purkinje cells and other neurons degenerate
remain unclear.
Disease-causing mutations and genotype-phenotype 
relationships
The Niemann-Pick type C disease variation database [87]
listed by January 2010 244 NPC1  and 18 NPC2  gene
sequence variants. Reporting from diagnostic laborato-
ries, however, has not been exhaustive, and the current
number for identified NPC1 disease-causing mutations is
most likely close to 300. More than 60 polymorphisms of
NPC1 have also been described, some of them very com-
mon. In early genetic complementation studies, it wasVanier Orphanet Journal of Rare Diseases 2010, 5:16
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stated that about 95% of the families had mutations in the
NPC1 gene [14]. In France, among the 132 families geno-
typed so far, 9 had NPC2 mutations. To date, only c:a 30
families have been identified worldwide with mutations
in the NPC2 gene. Several large mutational studies have
been published [33,47,82,87-97], but only few functional
studies [47,82,91,98-101].
The NPC1 gene, mapped to chromosome 18q11-q12,
spans 56 kb and contains 25 exons. One mutant allele,
p.I1061T, is particularly frequent [26] (approximately 20-
25% of alleles in patients diagnosed in France or the
United Kingdom). This mutation is also highly prevalent
in patients from a Spanish-American isolate from the
upper Rio Grande valley, but much less frequent in Portu-
gal, Spain or Italy [91,94,96]. In the homoallelic state, it is
associated with prominent cellular cholesterol trafficking
abnormalities in fibroblasts of patients, and it correlates
with a juvenile neurologic onset form of the disease [26].
In the heteroallelic state, so far it has never been found
associated with the most severe infantile neurologic onset
form. The I1061T mutant was shown to be a functional
protein selected for endoplasmic reticulum-associated
degradation due to protein misfolding and thus a poten-
tial target for chaperone therapy [98]. The second most
recurrent  NPC1  mutation in Europe, p.P1007A, is the
prototype of a "biochemical variant" mutation [47,89,95].
In the homozygous state, it has been described in a family
with two adult onset siblings [91]. A number of other
recurrent  NPC1 mutations seem to be associated with
adult neurological onset of the disease [35,95]. The muta-
tion p.G992W, typical of Nova-Scotian patients [17] is
sporadically (but rarely) found in patients of other origin.
As more patients are genotyped, a larger number of
recurrent mutations are observed, some of them prefer-
entially found in patients from defined ethnic origin.
The few genotype-phenotype studies published so far
in NP-C1 patients generally showed good correlation
between nonsense or frameshift mutations and the most
severe neurologic course. Missense mutations have
emphasized the functional significance of two particular
domains of the NPC1 protein. Homozygous mutations in
the sterol-sensing domain were found to be very deleteri-
ous, corresponding to a lack of mature NPC1 protein and
to a very severe disease phenotype, biochemically and
clinically [47]. The cysteine-rich luminal loop contains
approximately one third of all described mutations, with
a variable cellular and clinical impact [47,89,93,95].
Among others, it harbors the three most frequent muta-
tions discussed above. Interestingly, mutations leading to
a less severe impairment of cellular trafficking ("variant"
phenotype) are typically located on this loop
[47,90,91,93-95]. Genotype-phenotype correlations for
more specific mutations have been discussed in earlier
reports [11,88,95].
The NPC2 gene (initially known as HE1), mapped to
chromosome 14q24.3, spans 13.5 Kb and contains 5
exons [16]. One nonsense mutation (E20X) appears rela-
tively frequent [82,92], and many other mutations also
lead to a truncated protein. They have so far been associ-
ated with very severe clinical phenotypes. Described mis-
sense mutations have corresponded to more varied
phenotypes, including juvenile and adult onset patients
[82,92,93,101].
Finally, for both NPC1 and NPC2, the study of a large
number of multiplex families has clearly shown that
mutations correlate with the neurological form of the dis-
ease, but not with the systemic manifestations [11].
Diagnostic methods
The laboratory diagnostic algorithm proposed in a recent
consensus report [27] is given in Fig. 3.
Initial clinical assessment
Suspecting Niemann-Pick disease type C is relatively easy
in patients with the most typical symptoms, such as com-
bined splenomegaly, ataxia, and supranuclear vertical
gaze palsy. However, as described earlier, strikingly differ-
ent clinical presentations exist, especially in infants and
neonates. The fact that isolated spleno- or hepatospleno-
megaly can be the presenting symptom long before neu-
rologic onset has not been emphasized enough. Finally,
the diagnosis is often very delayed (and probably often
not made) in neurological cases lacking organomegaly,
and in psychiatric cases. Consequently, the age at which
the diagnosis is established is very variable. This is illus-
trated by data obtained in the author's laboratory for a
representative cohort of patients (Fig. 4).
The characteristic key signs and symptoms in the sys-
temic, ophthalmological and neuropsychiatric areas have
been discussed above and the reader is also referred to a
recent review [27]. A comprehensive clinical examination
should be performed. The neurological evaluation must
include muscle tone and strength tests, motor reflexes,
assessment of movement (ataxia and dystonia) and swal-
lowing testing [27]. Psychometric assessment is also
important.
The ophthalmological assessment is of particular
importance, because abnormal saccadic eye movements
(SEM) are often the earliest neurological sign in NP-C.
Proper examination is not always done, and reported
findings are sometimes neglected in the global evaluation
of the patient. The initial SEM deficit is in the vertical
plane (downward, upward, or both). VSGP can be
described as an increased latency of initiation of vertical
saccades, with gradual slowing and eventual loss of sacca-
dic velocity [27,102,103]. Subsequently, horizontal gaze is
also affected. Cataplexy ranges from subtle signs (minorVanier Orphanet Journal of Rare Diseases 2010, 5:16
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head-drop or falls, often confused with seizures) to full
collapse in response to humorous stimuli [27].
Neurophysiologic and neuroradiologic studies
Hearing tests (audiogram and/or brainstem evoked
potentials) often show abnormalities. MRI and CT scans
are not very useful for diagnosis, as they may be normal
or show cerebellar or cortical atrophy, or, in the severe
infantile form, white matter changes. Some rare patients
have been described with a peripheral neuropathy.
Histology
Foam cells and sea-blue histiocytes are usually - but not
always - present in bone marrow. Foam cells stain
strongly positive with filipin. Ultrastructural studies on
skin [104], conjunctival, or liver biopsies can provide
strong support for the diagnosis, but false-negative
results often occur on liver biopsy studied by light
microscopy only [41].
Non-specific laboratory analyses
Routine laboratory tests usually give normal results,
except in patients with cholestatic jaundice or hyper-
splenism. Low HDL-cholesterol is a frequent but not uni-
versal finding. Plasma lipid profiles seem correlated to
severity of cholesterol trafficking abnormalities [97]. Chi-
totriosidase activity is usually mildly elevated [105] but
can be normal. Acid sphingomyelinase activity is normal
or elevated in leukocytes (differential diagnosis with Nie-
Figure 3 Laboratory diagnosis algorithm. Footnote: This algorithm is as proposed in Wraith et al. Mol Genet Metab 2009, 98:152-165 [27] *Sphingo-
myelinase deficiency (including late-onset type A) may give a dubious filipin pattern, with normal kinetics of LDL-induced cholesteryl ester formation 
** False positive: I-cell disease (but very different clinical features) ***Heterozygotes may show a pattern (filipin staining and kinetics of LDL-induced 
cholesteryl ester formation) similar to that in "variant" patients ****In many countries, NPC1 p.P1007A or different missense mutations on codon 992 
constitute the most frequent "variant" mutations Genetic studies can also be undertaken if clinical symptoms are very suggestive of a diagnosis of NP-
C, even with negative results from filipin testing.
￿ Bone marrow  (useful, not mandatory): May show foam cells  (filipin + if tested for this stain)  
￿ If a liver biopsy is performed for cholestatic liver disease, fixation for EM study is essential
￿ Serum chitotriosidase: useful, not mandatory;  generally (not always) elevated activity
￿ Isolated (hepato)splenomegaly : enzymatic exclusion of Gaucher and Niemann-Pick B =  prerequisite (p ) p g y y pq
￿ Provide the laboratory with sufficient clinical data  (essential for correct interpretation of the results)
SKIN BIOPSY
– If local situation permits: fixation and EM study
– Fibroblast culture (mandatory) (y )
FILIPIN TEST
(cell biology) (done twice)
Highly positive 
« classical »
(85% of NP-C patients)
Moderately positive
with pure LDL, « variant »
(15% of NP-C patients)
Difficult Interpretation* 
(3-5% of NP-C patients)
Clearly negative
Re-assess clinical features Nearly sure NP-C** Probable “variant” NP-C***
Kinetics of LDL-induced 
cholesteryl ester 
formation
a priori, not NP-C
NPC1 Gene
Mutation p.P1007A
****
Reference Centre Complementary
investigations
If likely diagnosis, gene sequencing
and codon 992****
Sequencing of NPC1 and NPC2 genes
￿ Depending on countries study first NPC1 p I1061T or other most prevalent common mutation ￿ Depending on countries, study first NPC1 p. I1061T or other most prevalent common mutation
￿ Conclude quickly on NPC2 if child < 8-10 months
￿ NPC1: numerous polymorphisms!!! – check allele segregation from parental study
￿ often need to study both gDNA and cDNAVanier Orphanet Journal of Rare Diseases 2010, 5:16
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mann-Pick type B or atypical type A) but often partially
deficient in fibroblasts [11,25,29,67].
Specific laboratory diagnosis
Biochemical/cell biology study: the "filipin" test
The demonstration of impaired intracellular cholesterol
transport and homeostasis is considered the primary
diagnostic test for NP-C. These studies require living
cells and thus a skin fibroblast culture. They should be
conducted in specialized centres with the required expe-
rience. The "filipin test" is the most sensitive and specific
assay. Fibroblasts are cultured in a LDL-enriched
medium, then fixed and stained with filipin (a compound
forming specific complexes with unesterified choles-
terol). Fluorescence microscopic examination of NP-C-
positive cells typically reveals numerous strongly fluores-
cent (cholesterol-filled) perinuclear vesicles. This "classi-
cal" storage pattern is observed in approximately 80-85%
of cases. A lesser (and variable) level of storage is seen
even under optimized conditions [67] in the remaining
cases, described as having a "variant" biochemical pheno-
type [67,68]. As discussed above, several recurrent NPC1
mutations are known to result in this "variant" biochemi-
cal phenotype. Note that a similar, mildly abnormal filipin
pattern, has been observed in a number of heterozygotes
[69,70], but also not infrequently in acid sphingomyeli-
nase deficiencies. Measurement of the LDL-induced rate
of cholesteryl ester formation was until recently system-
atically used as a secondary test, showing very low levels
in cell lines with a "classical" biochemical phenotype but
only a mild or non-significant impairment in those with a
"variant" phenotype [67,68]. As this test is complex, costly
and time-consuming, mutation analysis is now often ini-
tiated directly when the filipin study is clearly positive.
From the experience of the author, based on the study of
cells from more than 600 NP-C patients, demonstration
of cholesterol accumulation in cultured fibroblasts pro-
vides a clear-cut diagnosis in a majority of cases, but
making a decision can be very difficult in some cell lines
showing only minor abnormalities. In such cases, (and
eventually in cases with apparently negative filipin but a
history highly suggestive of NP-C), complementary
mutation analysis is very useful to reach a definitive diag-
nosis.
Genetic testing
It is highly advisable to undertake gene testing in every
newly diagnosed patient, since molecular genetic study is
today the highly preferred strategy for prenatal diagnosis,
and the only reliable one for identification of carriers in
b l o o d  r e l a t i v e s.  F u r t h e r m o r e ,  a s  d i s c u s s e d  a b o v e ,  g e n e
testing can sometimes be necessary to confirm or dis-
prove the diagnosis of NP-C. Genetic complementation
studies - performed earlier in a few laboratories to define
which gene was affected - are no longer used today,
because cell hybridization and further testing are more
elaborate than gene sequencing. Sequencing of all exons
and boundaries is more laborious for the NPC1 gene (25
exons) than for the NPC2 gene (5 short exons), which is
unfortunate, since over 95% of NP-C patients have patho-
logical NPC1 mutations. Rapid methods have been pub-
lished to test for the two most frequent mutations [26,47].
Identification of NPC1 mutations can, in some instances,
be difficult and may require combined studies of gDNA
and cDNA. All groups have met a common problem,
namely that in some patients mutations could be identi-
fied in only one allele, and in a few of them, no mutation
at all. The latter patients have raised the question of a
potential third gene causing NP-C. This cannot be
excluded, but often the possibilities of large deletions, or
of deep intronic mutations [106] have not been investi-
gated. Finally, due to the highly polymorphic nature of
NPC1, interpretation of new missense mutations should
be undertaken with caution.
Differential diagnosis
In the neonate and young infant, Niemann-Pick disease
type C must be differentiated from idiopathic neonatal
hepatitis, and other causes of cholestatic icterus. Onset of
cholestasis usually occurs in the early neonatal period.
Associated splenomegaly is a useful orientation sign. In
c a s e  o f  i s o l a t e d  s p l e n o m e g a l y  o r  h e p a t o s p l e n o m e g a l y ,
NP-C should be considered as a possible cause. Among
other lipidoses, the most obvious differential diagnoses
are Niemann-Pick type B (similar foam cells in bone mar-
row) and Gaucher disease. In older children and adults,
depending on the symptoms, other conditions with cere-
bellar ataxia, dystonia, cataplexy and supranuclear gaze
palsy need to be considered [27,31].
Figure 4 Age at diagnosis vs life span. Study in a cohort of 141 pa-
tients originating from French hospitals. Each horizontal bar depicts 
one patient. The change of color shows at which age the diagnosis was 
established. Median: 3.1 years; 0-9 months: 30%; < 2 years: 36%; < 5 
years: 60%; > 16 years: 12%
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Genetic counseling
Niemann-Pick C disease is genetically inherited following
an autosomal recessive mode. The genetic status of a
blood relative can be reliably established if mutations
have been identified in the family index case. However, it
is not currently possible to ascertain the status of a per-
son from the general population, due to the complexity of
NPC1  gene sequencing and its polymorphic nature.
Antenatal diagnosis is possible under the conditions
described below.
The possibility of symptomatic heterozygotes has been
raised in three families known to the author but ruled out
in two of them (no further study in the third one). Two
disease-causing NPC1 mutations had been identified in
each index case. In both families, the father of the
proband developed progressive symptoms compatible
with an adult onset neurologic form of NP-C. Subsequent
complete gene sequencing revealed one allele carrying
the mutation transmitted to the affected child, and
another (not transmitted) disease-causing mutation on
the other allele (M.T. Vanier and K. Harzer; M.T. Vanier
and A. Ivanoiu, unpublished). These individuals were
thus NP-C1 homozygotes with an adult onset form.
These exceptional histories illustrate some of the prob-
lems eventually posed by the clinical heterogeneity of
NP-C and the possible underestimation of adult-onset
form of the disease.
Antenatal diagnosis
Prenatal diagnosis of NP-C should be offered to couples
at risk [27,107,108]. It is best achieved using chorionic vil-
lus sampling (CVS) at 10-12 weeks, but is also possible on
amniotic cells. Molecular genetic analysis is today by far
the preferred strategy [27], for several reasons. Unlike the
cellular biology testing using filipin staining, it does not
require cultured cells and a lengthy elaborate work up.
The results can be obtained much earlier in pregnancy,
and the tests can in principle be set up in any good
molecular biology laboratory. It however requires that
mutations have been identified on both alleles in the
index case, or at least that suitable intragenic markers
have been identified in the nuclear family. Today, few lab-
oratories offer a prenatal test using the cellular biology
strategy, which should be considered as a last resort due
to its many drawbacks. Results will not be reached until
5-7 weeks after the sampling; the tests are technically dif-
ficult; besides, they are fully reliable only when the
proband has shown severe abnormalities, thus excluding
15-20% of the families.
Management including treatment
To date, management remains largely symptomatic.
Information and support to families can be obtained
through organizations specifically devoted to Niemann-
Pick diseases (in the United States, United Kingdom,
Germany, Spain, Italy, Argentina, Australia, Poland), to
lysosomal diseases (France) or to inherited metabolic dis-
eases (The Netherlands) [see appendix for websites].
Genetic counseling should be made available for family
members. For detailed guidelines on current manage-
ment of patients, the reader is referred to a recent publi-
cation compiled by an international working group [27].
A study on the cost of illness associated with NP-C in the
UK has recently been published [109].
Symptomatic management
Seizures generally respond at least partially to antiepilep-
tic drugs until a fairly advanced stage of the disease. Cata-
plexy can usually be controlled by clomipramine,
protriptyline, or modafinil. Anticholinergic agents have
been reported to improve dystonia and tremor in some
patients. Physiotherapy is useful in the management of
spasticity and the prevention of contractures. Melatonin
may be used to treat insomnia. Patients with a slow dis-
ease course may benefit from special schooling for handi-
capped children. Proper management of infections and of
feeding difficulties (gastrostomy) is essential at an
advanced stage of the disease.
Specific treatment
In the murine and feline NPC1 models, bone marrow
transplantation (BMT) did not improve the neurological
disease, not unexpectedly considering the properties of
the NPC1 protein; similarly, after BMT the neurologic
status of a child continued to deteriorate, although there
was a regression of hepatosplenomegaly and lung infiltra-
tion [110]. In addition, liver transplantation performed in
a few cases with cirrhosis did not influence the course of
neurologic deterioration [111]. On the contrary, because
the NPC2 protein is soluble, secreted and recaptured,
there is a rationale supporting early hematopoietic stem
cell transplantation in NP-C2 patients [82]. The long-
term outcome is yet unknown, but encouraging results
have recently been obtained in one patient transplanted
at 18 months and followed up until 3 years of age [112].
Treatment strategies based on the hypothesis that cho-
lesterol is the offending metabolite were first proposed in
the early 90's. The combination of hypocholesterolemic
drugs and a low-cholesterol diet seemed to partially
reduce the cholesterol load in liver, but no amelioration of
the neurological disease was seen in patients after 2 years
of treatment [31].
Since glycolipid storage appears to contribute to at least
some of the neuropathologic features, an iminosugar
inhibitor of glucosylceramide synthase (miglustat, also
known as N-butyl-deoxynojirimycin, NB-DNJ and OGT
918, later approved for substrate reduction therapy of
mild to moderate type 1 Gaucher disease), was adminis-Vanier Orphanet Journal of Rare Diseases 2010, 5:16
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tered to npc1 mutant mice and cats. It resulted in delayed
onset of the neurological symptoms in both species, and a
20% longer survival of the mice [113]. A controlled clini-
cal trial was thus initiated in neurologically symptomatic
patients, first in adolescents and adults (12 years and
above) [114], then in children (4-12 years). Long-term
data from open-label extension treatment (up to 66
months) have now been reported in children [115] as well
as in juvenile and adult patients [116] (reviewed in [27]).
Overall, the disease course stabilized in 72% of patients
treated for one year or more, based on a composite
assessment of horizontal saccadic eye movement velocity,
ambulation, swallowing and cognition. In January 2009,
the European Union has extended the indication of
miglustat to the treatment of progressive neurological
manifestations in adult and pediatric patients with NP-C,
and the drug is now approved for this indication in sev-
eral other countries. This represents the first specific
treatment for NP-C. Apart from single case reports
[117,118], an international, multicenter observational
cohort study in 66 patients treated off-label with miglus-
tat has been published [119]. Evaluation made with a
modified disease-specific disability scale [32] further
showed a significant reduction in the annual rate of pro-
gression of the disease in a majority of patients. Late-
onset forms generally appeared as the best responders. A
further case series from Spain has been documented
[120]. Longer term studies will be important to better
evaluate the disease progression following the stabilisa-
tion phase [121]. Indication, clinical utility and monitor-
ing of treatment with miglustat have been recently
discussed [27,122]. In short, it has been recommended to
treat patients as soon as they show neurological manifes-
tations of any type. Due to the known adverse effects,
such as diarrhea, flatulence, weight loss and tremor, it is
not recommended today to treat patients with systemic
disease only. Note that miglustat is not expected to have
an effect on the systemic manifestations of NP-C.
Disease monitoring
In order to monitor disease progression and, if applicable,
patient responses to treatment, it is important to regu-
larly quantify the degree of disability resulting from neu-
rological impairment. Two disease-specific disability
scales have recently been proposed [32,123]. The first one
[32] (Table 1) evaluates four key parameters: ambulation,
manipulation, language and swallowing, with a 4 to 5
point scale for each. This allows calculation of a compos-
ite score representing overall "functional disability".
Although not formally validated, it has already been used
successfully in several cohort studies. Recent natural his-
tory surveys using these different scales both concluded
to a linear clinical progression over time [123,124]. The
cohort including a broader - and thus more representa-
tive - range of clinical phenotypes [124] showed a more
rapid course in the patients with an early onset.
Useful monitoring tests have been recently discussed in
detail [27]. Several methods for analysis of movement
abnormalities [125,126] or neuropsychological profiles
[127] have also been proposed. Results on three patients
indicated that longitudinal MRS studies [128] might
prove useful for follow up of therapy [129]. Diffusion ten-
sor imaging has also been proposed [130].
Experimental therapeutic approaches in animal 
models
Extensive research towards other therapeutic avenues is
currently underway on animal and cellular models. These
approaches have been reviewed in [27]. Various trans-
genic mice have been generated, such as mice over
expressing Rab9, a protein involved in intracellular traf-
ficking [131-133], or mice expressing NPC1 only in one
particular brain cell type [134]. Most studies have how-
ever been conducted on the npc1nih mouse and a cat
model (both spontaneous npc1  mutants) [135,136], as
well as a transgenic npc2 mouse mutant [18]. These ani-
mals are particularly useful to study brain dysfunction,
and facilitate various types of experiments, including
administration of various compounds with a therapeutic
goal. Data have been published in the mouse using ima-
tinib [137], curcumin [85], non-steroid anti-inflamma-
tory drugs [138], neurosteroids (allopregnanolone) in
combination with 2-HP-ß-cyclodextrin [139], and with 2-
HP-ß-cyclodextrin alone [64,140]. Chronic subcutaneous
administration of high doses of 2-HP-ß-cyclodextrin
resulted in a striking reduction of the various stored lip-
ids both in the liver and the brain of NP-C mice, as well as
a very significant effect on their lifespan [64]. An orphan
drug designation has been seeked for this compound
from the US-FDA. However, translation of most of these
studies to human patients is not straightforward. Even
neglecting adverse effects [141] or the purity or homoge-
neity of certain compounds, a quite general and major
limitation is the usual early timing of treatment (usually
long before symptoms appear). Such experimental work
in the whole animal is, however, important as it is gener-
ally felt that future treatment plans will combine several
approaches and will be tailored to the individual.
Prognosis
NP-C is a severe disorder that invariably leads to prema-
ture death, with few exceptions (three proven cases aged
53 years or more with isolated splenomegaly are known)
[45-48]. However, as discussed above, the rate of progres-
sion and life span show considerable variation. The sys-
temic disease can be fatal in early infancy. Patients with
fetal hydrops survive at most a few days. Liver failure
causes rapid death (before 3-6 months of age) in approxi-Vanier Orphanet Journal of Rare Diseases 2010, 5:16
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mately 10% of neonates presenting with a cholestatic ict-
erus, and a few patients (most of them with a severe
NPC2 mutation) have died from severe pulmonary insuf-
ficiency. Neonatal cholestatic icterus is otherwise tran-
sient and usually resolves spontaneously by 4 months of
age. Splenomegaly very rarely leads to hypersplenism. An
important observation is that the age of onset of the sys-
temic disease is generally unrelated to the subsequent
neurological involvement and cannot be used as a predic-
tor. This is well illustrated in Fig. 4, where several patients
diagnosed in their first months of life are now teenagers.
In the vast majority of patients, the lifespan is in large
part determined by the age of onset of nervous system
involvement. Data on large cohorts of patients recently
compiled for Spain, the UK and France [27] are well in
line with earlier reports. Patients with the severe neuro-
logic early infantile form often die between 3 and 5 years
of age, those with a late-infantile neurologic onset usually
between 7 and 12. Patients with a juvenile neurologic
onset survive until adolescence or later, with a sizable
proportion reaching the age of 30. In a review of 68 cases
with adult onset [35], the mean age at death (on 20
patients) was 38 ± 10.2 years, but some patients have
reached the age of 70. Motor involvement is often more
severe and more rapidly progressive than mental retarda-
tion. Progressive and severe dysphagia requiring gastros-
tomy is a common complication. Severe and intractable
epilepsy accelerates the downhill course of the disease.
Psychiatric disturbances, in rare cases, may be prominent
or even dramatic.
Regarding recurrence within a sibship, the study of
many multiplex families has shown that as a rule, the
neurological form - as defined by age of onset of neuro-
logical symptoms, and irrespective of the age of onset of
the systemic disease - is similar between siblings. The
subsequent course can however show variations, espe-
cially for cases developing severe epilepsy. On the other
hand, there are many examples of families with one case
of fetal hydrops or fatal neonatal liver disease and a sib-
ling having a more classical neurovisceral form - more
often of the early infantile type, but also of the late infan-
tile or juvenile type.
Correlations between the neurological form and the
severity of the cholesterol trafficking lesion as found by
the filipin test has been discussed previously [11,67,70].
In brief, in the experience of the author, a "variant" bio-
chemical phenotype tends to correlate with a less rapid
course, since it has so far never been found in the most
severe early infantile neurological form, is rare in late
infantile forms, but seen in a number of juvenile and
nearly half of the adult onset patients. On the other hand,
finding a very severe cholesterol trafficking impairment
(massive cholesterol accumulation in lysosomes) is not
predictive of any form of the disease (seen in the other
half of adult-onset patients).
Finally, although genotype-phenotype correlations are
limited, in NP-C1, some degree of prediction is often pos-
sible. Thus far, the p.I1061T allele has not been associated
with the most severe infantile neurological form [11,47].
Frameshift or nonsense mutations, as expected, but also
Table 1: NP-C functional disability scale (from[32] and [27])
Ambulation Score Language Score
Normal 1 Normal 1
Autonomous ataxic gait 2 Mild dysarthriad 2
Outdoor assisted ambulation 3 Severe dysarthriae 3
Indoor assisted ambulation 4 Non-verbal communication 4
Wheelchair bound 5 Absence of communication 5
Manipulation Swallowing
Normal 1 Normal 1
Slight dysmetria/dystoniaa 2 Occasional dysphagia 2
Mild dysmetria/dystoniab 3D a i l y  d y s p h a g i a 3
Severe dysmetria/dystoniac 4 NG tube or gastric button 
feeding
4
Abbreviation: NG, nasogastric; a autonomous manipulation; b requires help for tasks but able to feed self; c requires help for all activities; d 
understandable; e only comprehensible to certain family members.Vanier Orphanet Journal of Rare Diseases 2010, 5:16
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missense mutations affecting the sterol sensing domain
usually have a severe impact. On the other hand, associa-
tion with a mutation leading (when in the homozygous
state) to an adult onset form usually results in a slowly
progressive juvenile or early adult onset form [95].
Unresolved questions
NP-C is a disease with many unresolved questions. To
begin with, the precise and complete function(s) of the
NPC1 and NPC2 proteins are still largely unknown. Only
few studies on cholesterol transport and metabolism have
addressed the brain, in spite of the fact that brain has a
cholesterol metabolism that is different from that in cells
from systemic organs [142]. The nature of the primary
offending metabolite in brain is also unknown. For these
reasons, meaningful high throughput drug screening
strategies are difficult to set up.
A major practical problem is the current lack of a bio-
chemical test with sufficient specificity to be used for
screening - or even better, diagnosis - that could be car-
ried out on a blood sample. Having to start from a skin
biopsy excludes NP-C from all "metabolic screens" and
significantly contributes to the delay in diagnosis. Impor-
tantly, a recent pilot study indicates that plasma of
patients with NP-C show a specific oxysterol profile that
could be used as a biomarker [143]. This observation may
impact the future diagnostic strategy.
As regards therapy, because the NPC1 protein, unlike
many other lysosomal proteins, is not secreted and recap-
tured, many therapeutic strategies that are currently
holding promises for the future seem not easily applicable
to NP-C, including cell and gene therapy. Another diffi-
culty to treat the brain dysfunction is the unknown
nature of the primary targets. Along this line, the poten-
tial mode of action of some experimental compounds
(among which is ß-cyclodextrin) remains a puzzling
question. Finally, the broad clinical spectrum, as well as
the lack of good disease markers and clinical endpoints,
makes evaluation of therapeutic trials particularly diffi-
cult.
List of abbreviations
CT: computerized tomography; 2-HP-ß-cyclodextrin: 2-
hydroxypropyl-ß-cyclodextrin; LDL: low-density lipopro-
teins; NP-C: Niemann-Pick type C; NP-C1: Niemann-
Pick type C disease with mutations in the NPC1 gene;
NP-C2: Niemann-Pick type C disease with mutations in
the NPC2 gene; MRI: magnetic resonance imaging; MRS:
magnetic resonance spectroscopy: VSGP: vertical supra-
nuclear palsy.
Appendix
Niemann-Pick diseases support groups and correspond-
ing websites
1. Specific Niemann-Pick diseases support groups:
UK: Niemann-Pick disease Group (UK) http://
www.niemannpick.org.uk
USA and Canada: National Niemann-Pick disease
Foundation (USA): http://www.nnpdf.org; "Canadian
chapter": http://www.nnpdf.ca Ara Parseghian Medical
Research Foundation : http://www.parseghian.org
Germany: Niemann-Pick Selbshilfegruppe
Deutschland : http://www.niemann-pick.de
Spain : Fundacion Niemann-Pick de España : http://
www.fnp.es
Italy: Associazione Italiana Niemann-Pick: http://
www.niemannpick.org
Australia: Australian NPC disease Foundation: http://
www.npcd.org.au
Argentina: Asociacion Niemann-Pick Argentina: http:/
/www.npc.org.ar
Poland : Stowarzysenie Chorych na NPC
2. Support groups for Lysosomal Diseases or Inborn
Errors of Metabolism with a specific Niemann-Pick sub-
group:
France (with antennas in French speaking areas of Bel-
gium and Switzerland): Vaincre les Maladies Lysosomales
http://www.vml-asso.org
The Netherlands :Volwassenen Kinderen en Stofwis-
selingsziekten : http://www.stofwisselingsziekten.nl
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